Mechanism of Action Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa (FXa) in both the intrinsic and extrinsic coagulation pathways. The average wholesale price (AWP) for a package containing 4 vials is $13,200. Exposures and intoxications can affect humans, domestic animals and wildlife. Consequently, they are considered to … Now he is found laying on his stomach, on the sidewalk. Dose* of Kcentra (Units of Factor IX) / kg body weight 25 35 50 Maximum dose (units of Factor IX) Not to exceed 2500 Not to exceed 3500 Not to exceed 5000 . Vitamin K antagonist Factor Xa (FXa) inhibitor Direct thrombin inhibitor. However, in order to inactivate thrombin, heparin must bind to thrombin and AT simultaneously, an effect that occurs only when the molecule exceeds 18 monosaccharide units (greater than 6000 daltons). FEIBA controls bleeding by induction and facilitation of thrombin generation, a process for which FV is crucial. Angioedema may be divided into histamine-mediated versus bradykinin-mediated etiologies. Kcentra contains the vitamin K—dependent coagulation factors II, VII, IX, and X—together known as the prothrombin complex—and the antithrombotic proteins C and S. The coagulation cascade is a series of procoagulant and antithrombotic reactions involving the activation of … Kcentra is for use in adults and dosing is based on body weight. Chapter 2: Setting the stage and calculating the treatment dose. Onset: 1-72 hr. • Kcentra decreased INR to ≤ 1.3 within 30 minutes in most subjects (62%) in clinical trials – Long duration of action (> 24 hours) • Disadvantages – More expensive (~$1.27/unit (average cost for 80kg patient = “Mechanism of action and reversal strategies for 医療関係者の方に向け、日本初のビタミンK 拮抗薬療法中の迅速なPT-INR是正・止血をサポートする4-Factor PCC「ケイセントラ静注用」についての情報をお届けしています。このページではケイセントラの動画についてご紹介します。-CSLベーリング By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate . (A) Mechanism of action of idarucizumab. Exhibits antiplasmin activity. VKAs: mechanism of action. Login. Arterial Dilators. Menadiol is a water soluble form of vitamin K; phytonadione has a more rapid and prolonged effect than menadione; menadiol sodium diphosphate (K 4) is half as potent as menadione (K 3). The mechanism of action of PCCs is important for understanding their therapeutic applications. pts on vitamin K antagonists (VKA) tx have underlying dz states that predispose them to thromboembolic events; weigh benefits of reversing VKA vs. thromboembolic event risk, esp. is report will brie y review the mechanism of action of the oral anticoagulants, present our bleeding manage-ment protocols, and discuss the rationale for our use of prothrombin complex concentrates and rfVIIa in refractory hemorrhage. DESCRIPTION. Airway angioedema can be fatal; therefore, prompt diagnosis and correct treatment are vital. Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants; Factor VII stimulants; Factor X stimulants; Protein C inhibitors; Prothrombin stimulants. Its kinetics are horribly unpredictable. Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S. A dose-dependent acquired deficiency of the Vitamin K-dependent coagulation factors occurs during Vitamin K antagonist treatment. 1. This report will briefly review the mechanism of action of the oral anticoagulants, present our bleeding manage- ... (Kcentra)inthesettingofrivaroxaban-associatedrefractory bleeding. REFERENCES Kcentra (4 factor PCC) 50 units/kg 2. See Table 3 for dosing. Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. 12.1 Mechanism of Action 12.3 Pharmacokinetics NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES Hemophilia A without FVIII Inhibitors 14.2 Hemophilia A with FVIII Inhibitors 16 HOW SUPPLIED/STORAGE AND … Kcentra (CSL Behring, King of Prussia, PA)† Mechanism of action Restores intrinsic clotting factor production Restores all clotting factors Triggers the final common pathway of the clotting cascade. Kcentra is therapeutically equivalent to Beriplex, which has been marketed outside of the US since 1996. Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Low molecular weight heparins (LMWHs) have a similar mechanism of action of heparin and retain the ability to inactivate factor Xa. Orphan Drug Status. Andexxa (c) is supplied through Portola Pharmaceuticals Inc. as a lyophilized powder in single-use vials containing 100 mg coagulation factor Xa recombinant, inactivated zhzo. The efficacy of 25 to 50 U/kg of four-factor PCC (Kcentra) for reversal of elevated INR in warfarin patients has recently received FDA approval. Kcentra (prothrombin complex) is a blood coagulation factor replacement product. mechanism of action The coagulation cascade is a series of procoagulant and antithrombotic reactions involving the activation of zymogens. Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S. A dose-dependent acquired deficiency of the Vitamin K-dependent coagulation factors occurs during Vitamin K antagonist treatment. Kcentra has not been studied in patients with congenital factor deficiencies. warfarin (Coumadin®) 4F-PCC* (Kcentra®) Dosing for Kcentra was obtained from the package insert. Kcentra (4 factor PCC) 50 units/kg 2. Chapter 4: Dosing and administration using 100-mg vials. Chapter 3: Reconstitution of the 100-mg vials. I want to blast the clotting system back into action. Mechanism of Action Direct thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor Bioavailability (%) 3-7 66-100 50 62 34 Prodrug Yes No No No No Protein Binding (%) 35 >90 87 55 60 Half-life (hours) 12-17 5-9 8-15 10-14 19-27 Route of Elimination 80% renal 33% renal 25% renal 50% renal 11% renal Nadir was measured between 5 minutes after bolus until the end of the infusion 1; Rate of excellent or good hemostatic efficacy 12 hours after infusion. Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Approved for treatment of hemophilia B (factor IX deficiency) The cost of Kcentra® is $1.27 per unit; a single dose of Kcentra® for an 80 kg patient costs $5,080. There may be more sustained warfarin resistance down the road, bur our concern in this patient is dead versus not dead. Some versions also contain factor VII. 22 Efficacy and safety of Kcentra have been evaluated in 2 prospective, open-label, randomized, plasma-controlled trials. 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Adjunctive Treatment of Major Depressive Disorder 14.2 Schizophrenia 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied 16.2 Storage Percent change in anti-FXa activity, from baseline to nadir. Arterial and Venous Thromboembolic Complications. By 24 hours, INR will be the same after administration of low dose IV or PO vitamin K, but IV vitamin K starts working The widespread use of these molecules raises questions on exposure and intoxication risks, which define the safety of these products. Although KCentra – a 4-factor prothrombin complex concentrate – is the only product with FDA approval for rescuing patients taking warfarin, it is significantly more expensive than FFP, leading many institutions to adopt the cheaper product. Angioedema is a common presentation in the emergency department (ED). The exact mechanism whereby PCC may improve hemostasis under activated factor X inhibition has not been clarified yet. This recombinant protein (r-Antidote, PRT064445) is ca … Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Every oral anticoagulant has a reversal agent with a distinct mechanism of action within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Mechanism of Action. 32 The recommended Kcentra dose of 50 IU/kg is equivalent to ~1.0 IU/mL 4F‐PCC plasma level. Mechanism of Action Understanding the mechanism of action of … (B) Structure and mechanism of action of andexanet alfa. Kcntra costs roughly $1.27 per unit. Mechanism of Action/Pharmacology 2-4 . Mechanism of action. Kcentra is used to quickly reverse the effects of a blood-thinning medicine (such as warfarin) during a major bleeding episode, or when there is a need for emergency surgery or invasive medical procedure. Common Trade Names: Kcentra. The mechanism of action is very pinpointed and directed at 1 molecule rather than warfarin, or Coumadin, which may affect multiple factors. Mechanism of Action. Andexxa (c) is supplied through Portola Pharmaceuticals Inc. as a lyophilized powder in single-use vials containing 100 mg coagulation factor Xa recombinant, inactivated zhzo. References:1-4 1. Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S. • Kcentra decreased INR to ≤ 1.3 within 30 minutes in most subjects (62%) in clinical trials – Long duration of action (> 24 hours) • Disadvantages – More expensive (~$1.27/unit (average cost for 80kg patient = ... “Mechanism of action and reversal strategies for 1 NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues (MW 50 K Dalton). Kcentra is a four-factor prothrombin complex concentrate (4F-PCC) of coagulation factors II, VII, IV, and X, prepared from U.S. sourced plasma. A number of biochemical in vitro and in vivo studies have shown that FXa and prothrombin play a critical role in the activity of FEIBA. Based on the findings of two expert panels attended by international experts in angioedema and emergency medicine, this review aims to provide practical guidance on the diagnosis, differentiation, and management of … uregent warfarin reversal with fast and sustained action rapid INR reduction to less than 1.3 at .5 hours after end of infusion. Kcentra - Clinical Pharmacology Mechanism of Action. If you're not in a hurry, PO is an excellent option. Pharmacy Resources • American College of Chest Physicians Vitamin K antagonists such as warfarin function by reducing levels of four coagulation factors: II, VII, IX, and X, with the aim of preventing thromboembolism. PCC is a sterile, lyophilized concentrate of factors II, VII, IX, and X and protein C and S. Prior to development of FIX concentrates, PCC with low amounts of FVII (3-factor PCC) was used to treat hemophilia B. 36, 42–52 KCentra® (CSL Behring, King of Prussia, PA) is the only 4-factor formulation approved for this indication in the United States. In women ages 40 to 50, fibroids are commonly believed to cause menorrhagia . Anticoagulation Reversal in the Hemorrhagic Stroke Patient April 29th, 2016 Nicholas G. Panos, PharmD, BCPS Rush University Medical Center The off-label use of Kcentra, Feiba, Novoseven, tranexamic acid and aminocaproic acid will be discussed and I have no actual or KCentra as a means to reverse apixaban or rivaroxaban, against a targeted approach using Andexanet Alfa, which is associated with significantly more cost but which may be more efficacious given its mechanism of action. Kcentra is the only FDA-approved alternative to plasma for urgent warfarin reversal ... 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 15 REFERENCES We designed and expressed a modified form of fXa as an antidote for fXa inhibitors. Dabigatran is available as a prodrug, dabigatran etexilate, which is rapidly converted to … Exposures and intoxications can affect humans, domestic animals and wildlife. Kcentra is also contraindicated in patients with disseminated intravascular coagulation. This suggests that menorrhagia is related to increased estrogen action prior to onset of flow. The average wholesale price (AWP) for a package containing 4 vials is $13,200. Bruising under eyes & … Dabigatran is a reversible inhibitor of factor IIa (thrombin) that binds directly to the active site on the thrombin molecule. The widespread use of these molecules raises questions on exposure and intoxication risks, which define the safety of these products. Facilitates thrombin generation. Consequences are different for each group, from the simple … A commercially available 4F‐PCC (Kcentra/Beriplex, CSL Behring LLC, Kankakee, IL, USA) was added to PPP (0‐1.0 IU/mL). We support the Joint Commission's National Patient Safety Goal (NPSG) 03.05.01 pertaining to reducing harm from anticoagulant therapy. Heparin primarily impacts Factors IIa and Xa (via AT-III). Structure and mechanism of action of reversal agents. It directly relaxes the vascular smooth muscle in systemic arterioles by inhibiting calcium fluxes into the cell or by increasing local prostacyclin concentrations. 2013 Dec. Kcentra is also contraindicated in patients with disseminated intravascular coagulation. mechanism of action of warfarin. 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. Inhibitors of coagulation factor Xa (fXa) have emerged as a new class of antithrombotics but lack effective antidotes for patients experiencing serious bleeding. Given the mechanistic similarity and positive in vitrodata,wealsousea4-factorPCC(Kcentra)inpatients NovoSeven® Coagulation Factor VIIa Recombinant. Chapter 5: Follow-up care … Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial. Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. 2). Mechanism of action and pharmacokinetics. Several animal studies and a phase I trial have indicated that there is a dose-dependent effect, 34–37 but the mechanism of action can probably not be explained by a simple stoichiometric reaction. Pharmacodynamics: Mechanism of Action: The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. Anticoagulant Reversal agent Reversal agent MOA. Replaces FII, FIX, FX Replaces FII, FVII, FIX, FX. Mechanism of Action: Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S. A dose-dependent acquired deficiency of the Vitamin K-dependent coagulation factors occurs during Vitamin K antagonist treatment. Andexanet (dosing below) Edoxaban (Savaysa®) Reverse if patient shows signs of life threatening bleeding 1. It is usually taken with or without food three times a day for up to 5 days during monthly menstruation. 14 For low dose treatment (400 mg IV bolus plus 480 mg for 120-minute continuous infusion), the cost would be approximately $29,700 … Vd: 23 L (PO), 30 L (IV) Metabolism: Liver. Importantly, a mechanism for reporting inappropriate prescribing to hospital administration will provide valuable support to frontline clinicians charged with promoting adherence to the restrictions. VKAs primarily inhibit vitamin K epoxide reductase. Angioedema is a common indication for critical care admission. I –Pale. Mechanism of Action: Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S. A dose-dependent acquired deficiency of the Vitamin K-dependent coagulation factors occurs during Vitamin K antagonist treatment. 3 factor PCC (Factors II, IX, and X), would need to supplement with factor VII for reversal if using 3 factor PCC. Duration: 3-4 hr (after 1 dose) Half-Life: 2 hr. KCENTRA (Prothrombin Complex Concentrate (Human)) ... 12.1 Mechanism of Action 12.2 Pharmacodynamics. Onset of Action: Rapid Restricted to approval by Intensivists/ER Physicians for use in patients with intrcranial hemorrhage meeting all of the following criteria: -last dose of apixaban, rivaroxaban, or edoxaban within 18 hours-Glasgow Coma Scale Score ≥ 5-No administration of Kcentra, FEIBA or NovoSeven within 48 hours PROTAMINE First line It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. Kcentra is a sterile, heat-treated, non-activated, 35 nm nano-filtered, and lyophilized product, manufactured from a pool of human US source plasma. Mechanism of Action Acts on multiple pathways in the clotting cascade to facilitate coagulation in an in vitro analysis 2 In Vitro Analysis Multiple clotting factors of FEIBA achieved hemostasis in an in vitro analysis 2. Kcentra is a sterile, heat-treated, non-activated, 35 nm nano-filtered, and lyophilized product, manufactured from a pool of human US source plasma. Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown. • Kcentra • currently the only 4 PCC available in US • approved for urgent reversal of Vit K antagonist (warfarin) in acute major bleeding • thromboembolic events ~5-9% (vs. ~4-6% for FFP) • reversal can be achieved in 10-30 min Kcentra (Prothrombin Complex Concentrate) [prescribing information]. Mechanism of Action Direct thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor Bioavailability (%) 3-7 66-100 50 62 34 Prodrug Yes No No No No Protein Binding (%) 35 >90 87 55 60 Half-life (hours) 12-17 5-9 8-15 10-14 19-27 Route of Elimination 80% renal 33% renal 25% renal 50% renal 11% renal Kcentra has no evidence or mechanism of action to show that it works and nobody ever plans to apply to the FDA for Kcentra approval. 22 Efficacy and safety of Kcentra have been evaluated in 2 prospective, open-label, randomized, plasma-controlled trials. Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S; Kcentra should not be used in HIT as it contains heparin in the formulation. Mechanism of action. Mechanism of Action. Hydralazine is an arteriolar vasodilator, the mechanism of action of which is not clearly elucidated. Yes - Haemorrhage. Tranexamic acid comes as a tablet to take by mouth. 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY. The capacity to restore thrombin generation is critical to the mechanism of action of PCCs ... adult patients with acute major bleeding or need for an urgent surgery/invasive procedure (Table 2; Fig. Hydralazine has no effect on systemic venous tone. Kcentra (4 factor PCC) 50 units/kg Rivaroxaban (Xarelto®) Reverse if patient shows signs of life threatening bleeding and has an INR > 1.5 1. 医療関係者の方に向け、日本初のビタミンK 拮抗薬療法中の迅速なPT-INR是正・止血をサポートする4-Factor PCC「ケイセントラ静注用」についての情報をお届けしています。このページではケイセントラの動画についてご紹介します。-CSLベーリング When FXa is inhibited, clot formation is greatly reduced Class. Idarucizumab is a monoclonal antibody that binds dabigatran with high affinity preferentially over thrombin, and readily displaces dabigatran, allowing fibrin formation to occur normally . 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed. Prothrombin Complex Concentrate. Helping healthcare professionals by providing the most trusted drug and clinical information available, delivered across multiple platforms, and easily integrated into daily workflow. Chapter 1: In-hospital diagnosis and patient identification. Type: Hemostatics, blood components. Anticoagulant rodenticides (ARs) are a keystone of the management of rodent populations in the world. Kcentra is a 4-factor PCC , indicating it provides therapeutic levels of factors II, VII, IX, and X, whereas current PCCs provide little VII. Anticoagulants, commonly referred to as blood thinners, are drugs that prevent or reduce coagulation of blood, prolonging the clotting time. The mechanism of action is going to be directed to factor Xa inhibition via direct oral anticoagulants, except for dabigatran, which is a direct thrombin inhibitor or a factor IIa inhibitor. Kcentra contains the Vitamin K-dependent coagulation Factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the Prothrombin Complex, and the antithrombotic Protein C and Protein S. Additional Information Primary efficacy measures. Pharmacokinetics. And in a nutshell, that’s its mechanism of action. Kcentra® is dosed according to Factor IX potency and is individualized based on the patient’s baseline International Normalized Ratio (INR) and body weight. Consequences are different for each group, from the simple … Mechanism of action of Prothrombin complex concentrate (kcentra): The levels of the vitamin K-dependent coagulation factors (II, VII, IX, and X) protein C and protein S is increased by prothrombin complex concentrate. Anticoagulant rodenticides (ARs) are a keystone of the management of rodent populations in the world. Kcentra™ may be an option for eminent life threatening bleed due to rivaroxaban, apixaban, edoxaban, or dabigatran. Kcentra™ does contain heparin and may not be option in patients who are sensitive to heparin or have a recent diagnosis of heparin-induced thrombocytopenia. Inhibits fibrinolysis through inhibition of plasminogen binding to fibrin and subsequent conversion to plasmin, which in turn inhibits fibrinolysis. In 2013, the FDA approved Kcentra for the urgent reversal of acquired coagulation factor Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). So here's the thing with heparin. NovoSeven®is recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. Kcentra is the only FDA-approved alternative to plasma for urgent warfarin reversal ... 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 15 REFERENCES References:1-4 1. KCentra as a means to reverse apixaban or rivaroxaban, against a targeted approach using Andexanet Alfa, which is associated with significantly more cost but which may be more efficacious given its mechanism of action. kcentra is what. ... injection of vitamin k or kcentra. Mechanism of Action. ... no and it has a prolonged duration of action so the INR cannot be alterd quickly. 12.1 Mechanism of Action Pharmacodynamics Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility CLINICAL STUDIES. An allergist usually won't be immediately available, so the critical care practitioner must be adroit in management of these cases. It seems to affect everyone a little differently, and the only way for us to get around this is by monitoring. 14 For low dose treatment (400 mg IV bolus plus 480 mg for 120-minute continuous infusion), the cost would be approximately $29,700 … The neighbor called 911. It may also be used in those with not enough of these factors due to other reasons such as warfarin therapy. Mechanism of Action. 2. Mechanism of Action. However more estrogen action and less progesterone production cause fibroid growth as well as increased endometrial thickness . General. Progressive Case Scenario 1 –On Scene M –88 year-old male tripped over dog & fell. This leads to impaired recycling of reduced vitamin K resulting in decreased functional vitamin K dependent factors (VKDFs; factor II, factor VII, factor IX, factor X, and protein C and S), placing the patient in an overall anticoagulated state.
Otterkill Golf Course Scorecard, Www Nolo Com Back Of Book Quic Html, Military Base In South Carolina, Nba Playoff Buzzer Beaters List, Luxury Train Journey Mexico, Crunchyroll Anime Awards 2020 Nominees, Azurri Blue Rose Of Sharon Tree, Bellingham Police Department Jobs, Wine Decanter Crystal, 75th Communications Squadron,